Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis

American Heart Journal

Volumn 131, Issue 2, 1996, Pages 276-280

  Hirsch, Denise R ^a   Lee, Thomas H ^a   Morrison, Ruth B ^a   Carlson, William ^a   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST CONTROL; DEEP VEIN THROMBOSIS; FEMALE; HOSPITALIZATION; HUMAN; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030049089     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90354-3     Document Type: Article

References (12)

1. Doyle DJ, Turpie AG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med 1987;107:441-5.
2. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992;116:279-84.
3. Epi Info Version 5.01b. Atlanta, Ga.: Centers for Disease Control, Epidemiology Program Office, 1991.
4. Gardner MJ, Gardner SB, Winter PD. British Medical Journal Confidence Interval Analysis (CIA), Version 1.0. London, England: British Medical Journal, 1989.
5. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
6. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JMJ, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJM, Cohen AF. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 1992;86:1370-5.
7. Goldhaber SZ. Conjunctive heparin therapy: limitations of subcutaneous administration. Circulation 1992;86:1639-41.
8. Decousus HA, Croze M, Levi FA, Jaubert JG, Perpoint BM, De Bonadona JF, Reinberg A, Queneau PM. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985;290:341-4.
9. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153:1541-6.
10. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deepvein thrombosis. Lancet 1992;339:441-5.
11. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
12. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.